Charles Hadden
shared a link
2021-11-27 15:06:06 -
https://www.biopharmadive.com/news/merck-molnupiravir-final-results-covid/610597/
https://www.biopharmadive.com/news/merck-molnupiravir-final-results-covid/610597/
WWW.BIOPHARMADIVE.COM
New Merck study results raise questions about its COVID-19 pill
Final trial data for molnupiravir were less convincing than what Merck previously reported and could alter how the FDA views the drug, which will be evaluated at a meeting Tuesday.
0 Comments 0 Shares 849 Views
Please log in to like, share and comment!
Sponsored

We are 100% funded for October.

Thanks to everyone who helped out. 🥰

Xephula monthly operating expenses for 2024 - Server: $143/month - Backup Software: $6/month - Object Storage: $6/month - SMTP Service: $10/month - Stripe Processing Fees: ~$10/month - Total: $175/month

Xephula Funding Meter

Please Donate Here

© 2024 XEPHULA English
English Arabic French Spanish Portuguese Deutsch Turkish Dutch Italiano Russian Romaian Portuguese (Brazil) Greek
FAQ Contact About Terms Privacy Directory